News

AbbVie's Humira first-approved drug for chronic skin disease


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

AbbVie's Humira first-approved drug for chronic skin disease

Date: 05/08/2015

AbbVie’s aging rheumatoid arthritis drug Humira has been approved as the first EU treatment for the skin disease hidradenitis suppurativa (HS).

HS, which is also known as acne inversa, is a painful, chronic inflammatory skin disease characterised by recurrent, painful abscesses and nodules on the skin – typically around the armpits and groin, on the buttocks and under the breasts.

The European Comission approval is based on the PIONEER Phase III studies, which showed that patients given Humira (adalimumab) had greater reductions in the numbers of abscesses and inflammatory nodules than patients given placebo.

For more click here

Source: PharmaTimes

© Catalyst Innovation Portal 2019